FindTrial
Sign In

Dexmedetomidine infusion during Adult Living Donor Liver Transplantation

Intraoperative Effect of Dexmedetomidine infusion during Adult Living Donor Liver Transplantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201408000872245
Enrollment
40
Registered
2014-08-20
Start date
2013-10-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Surgery Donor Liver Transplantation

Interventions

Dexamedetomidine
Control

Sponsors

National liver institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Model for End-Stage Liver Disease (MELD) score 12-20. Living donor liver transplant recipients with no severe haemodynamic instability, normoxia, normothermia and no major intraoperative events.

Exclusion criteria

Exclusion criteria: Severe haemodynamic instability. Unwilling to participate in the study.

Design outcomes

Primary

MeasureTime frame
Anesthetic consumption—

Secondary

MeasureTime frame
Metabolic effects of dexmedetomidine—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com002-01223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026